Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25561335 | 0.86 | ALDH1A1 (0.39) | KMT2AKDM4EALDH1A1POLBGAA | |
| SCHEMBL22446022 | 0.78 | KMT2A (0.46) | KMT2AKDM4EALDH1A1POLBGAA | |
| SCHEMBL30233896 | 0.77 | KMT2A (0.33) | KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL30047263 | 0.71 | ALDH1A1 (0.52) | KMT2AKDM4EALDH1A1GAAHPGD | |
| SCHEMBL259951 | 0.71 | ALDH1A1 (0.52) | KMT2AKDM4EALDH1A1GAAHPGD | |
| SCHEMBL16836044 | 0.71 | KDM4E (0.56) | KMT2AKDM4EALDH1A1GAAHPGD | |
| SCHEMBL25554165 | 0.70 | PSEN1 (0.35) | — | |
| SCHEMBL13156056 | 0.70 | GAA (0.48) | KMT2AKDM4EALDH1A1GAAHPGD | |
| SCHEMBL19657936 | 0.70 | PIK3R1 (0.40) | KMT2APDE4B | |
| SCHEMBL25554169 | 0.69 | ALDH1A1 (0.43) | KMT2AKDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KMT2A 3772/4885KDM4E 3761/4885ALDH1A1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.